33 results about "AKT1" patented technology

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.

The invention relates to the field of genetic engineering and biotechnologic detection, and concretely relates to a gene group and a kit for diagnosing lung cancer, and a diagnosis method thereof. The gene group for diagnosing the lung cancer includes ABCB1, AKT1, ALK, APC, ATIC and other 63 genes. The method using the gene group to diagnose the lung cancer comprises the following steps: (1) extracting free DNA and genome DNA from the plasma of a sample to be detected; and (2) breaking the genome DNA into fragments with the length of 150-250 bp, carrying out hybrid capture on the broken genome DNA and the free DNA to construct a DNA library, carrying out online sequencing, and analyzing the obtained sequencing result. Exon and partial intron regions of the 68 genes of the free DNA are enriched at one time by a probe capture technology to realize multi-gene and multi-target parallel deep high-throughput sequencing with high accuracy, optimize the detection flow and improve the detection precision, so liquid biopsy, low-frequency detection and tumor diagnosis become possible.

The invention discloses a non-small cell lung cancer targeted therapy gene detection method, and belongs to the field of gene detection. The method for detecting 466 mutations of 12 oncogenes is developed by multiplex PCR and high throughput sequencing technologies, wherein the oncogenes are AKT1, ALK, BRAF, EGFR, ERBB4, FGFR1, FGFR2, FGFR3 , KRAS, MET, PIK3CA, and PTEN, and the mutations may be substitutions, insertions and / or deletions of one or more bases. The detection method provided by the invention has the advantages of high detection sensitivity of up to 0.01%, and clear and objective detection results, can be directly used for reflecting specific mutation sites of the relevant gene, directly used for guiding clinical non-small cell lung cancer targeted dosage, and used for early diagnosis or auxiliary diagnosis and screening of cancers as well as post-cancer surveillance.

The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the compounds with a target binding site; (3) ranking the docked compounds by goodness of fit; (4) further selecting compounds; (5) optionally, visually analyzing structures of compounds selected in step (4) to remove any compounds with improbable docking geometry; and (6) experimentally testing the selected compounds from step (4) or step (5), if step (5) is performed, to determine their inhibitory activity against Akt1. The invention also encompasses pharmaceutical compositions including compounds whose inhibitory activity against Akt1 is discovered by the screening method, as well as methods of use of the pharmaceutical compositions to prevent and treat cancer and other conditions.

The invention discloses a glioma detection panel based on next-generation sequencing, a detection kit and their application, wherein the glioma detection panel comprises glioma-related genes and loci;the glioma-related genes and loci include SNP (single-nucleotide polymorphism) locus on No. 1 chromosome, SNP locus on No. 19 chromosome, MGMT, ATRX, H3F3A, ACVR1, CTC, HIST1H3B, MLH1, PLCG1, SMO, AKT1, CTNNB1, HIST1H3C, MSH2, PMS2, TERT, ATRX, DAXX, HRAS, MSH6, PPM1D, TP53, BCOR, DDX3X, IDH1, MYC, PTCH1 and the like. The glioma detection panel herein is suitable for providing a patient with precise comprehensive diagnostic and treatment services just through next-generation sequencing.

The invention relates to tumor susceptibility 62 genes and application thereof. The tumor susceptibility 62 genes comprise PTEN, STK11, CDH1, TP53, BRCA1, BRCA2, PALB2, CHEK2, ATM, BRIP1, NBN, RAD51C, MLH1, MSH2, MSH6, PMS2, BARD1, RAD51D, MRE11A, MUTYH, PMS1, RAD50, XRCC2, AKT1, PIK3CA, FANCC, RECQL, CCND1, ERBB2, ESR1, GATA3, FGFR1, MAP2K4, MAP3K1, BAI3, CTNNB1, BRAF, KRAS, CTNNA1, EPCAM, APC, BLM, SMAD4, BMPR1A, POLD1, POLE, AXIN2, MEN1, KIT, EGFR, EZH2, PRF1, CDKN2A, CDK4, BAP1, RB1, ERCC2, VHL, MET, FH, FLCN and RET. The detection of the genes can be used for evaluating tumor susceptibility.

The invention relates to a kit for predicting colorectal cancer liver metastases and a use method. The kit includes a DNA database building kit, the DNA database building kit comprises probes of a plurality of genes, and the plurality of genes include: high risk genes: KRAS, BRAF, MLH1, NRAS, MSH2, PMS2, UGT1A1, MSH6 AKT1, PIK3CA, PTEN, SMAD4, TP53, NM23, TIAM1, MTS1; and low risk genes: PRKDC, RAD50, STAG2, XRCC5, XRCC6, FANCA, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1, XRCC1. The kit provided by the invention performs related mutation detection on colorectal cancer liver metastases related genes in peripheral blood, and combines specific scoring mechanism to rapidly and conveniently judge and predict colorectal cancer liver metastases.

The invention discloses a hormone receptor-positive breast cancer recurrence monitoring gene mutation library construction method, which is characterized that the library covers the total 1357 somatic cell mutations on human genes such as KRAS, JAK3, AKT1, CREBBP, PTEN, RB1, TP53, CTNNB1, TSC2, TSC1, ERBB2, PIK3CA, SF3B1, JAK2, CDH1, SMAD4, GATA3, MAP2K4, MAP3K1 and ESR1. According to the present invention, a plurality of the target sequences are subjected to single tube amplification with the construction method to rapidly complete the library construction, wherein the whole library construction process takes only 2-3 h and the manual time only needs 45 min, such that the difficulty that the multi-gene and multi-target detection of somatic cells on the basis of the small amount of the peripheral blood sample is required in the clinical breast cancer recurrence monitoring is required can be effectively solved, and the lost is low.

The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase, also known as Protein Kinase B, an enzyme that is believed to play a key role in the inhibition of apoptosis and thus in the etiology of cancer and other conditions, including neurodegenerative diseases. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the compounds with a target binding site derived from the crystal structure of a ternary complex involving Akt1, a nonhydrolyzable ATP analogue, and a peptide substrate derived from a physiological AKT substrate such that the protein active site is defined including those residues within a defined distance from the nonhydrolyzable ATP analogue; (3) ranking the docked compounds by goodness of fit; (4) further selecting compounds from compounds high ranked by goodness of fit in docking by using one or more screening criteria; (5) optionally, visually analyzing structures of compounds selected in step (4) to remove any compounds with improbable docking geometry; and (6) experimentally testing the selected compounds from step (4) or step (5), if step (5) is performed, to determine their inhibitory activity against Akt1 in order to select compounds with Akt1 inhibitory activity. The invention also encompasses pharmaceutical compositions including compounds whose inhibitory activity against Akt1 is discovered by the screening method, as well as methods of use of the pharmaceutical compositions to treat cancer and other conditions.

The invention discloses a system for predicting the prognosis of a patient with lung squamous cell carcinoma. The system includes a subsystem for detecting the expression quantity of such five proteins as EGFR, p38alpha, AKT1, SOX2 and E-cadherin and a protein expression quantity data processing system. The subsystem for detecting the expression quantity of the five proteins is allowed to measure the expression quantity of the proteins through an immunohistochemistry staining method; the protein expression quantity data processing system is allowed to convert the expression quantity of the five proteins from the squamous cell carcinoma tissues separated from the patient with the lung squamous cell carcinoma to a prognostic score; based on the prognostic score, the prognosis of a patient with the lung squamous cell carcinoma is predicted.

The invention discloses a capturing and sequencing method for multiple genes related to capillary malformation. The method at least includes the steps of genomic DNA extraction and fragmentation, fragmental DNA end filling, linker connection, pre-capturing PCR, hybrid capturing, and post-capturing PCR. The selected genes related to human capillary malformation include ACVRL1, AKT1, ENG, EPHB4, GNA11, GNAQ, KRAS, MAP2K1, NRAS, PIK3CA, PTEN, RASA1, SMAD4 and TEK; by combining the gene capturing technology with the high-throughput sequencing technology, all variant types of target genes can be detected, including mutation, deletion, insertion and fusion.

A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.

The invention provides a PCR reagent for detecting gene expression of an angiogenesis signal channel and an application thereof. The PCR reagent comprises PCR reaction primers for detecting AKT1 genes, ANG genes, ANGPT1 genes, ANGPT2 genes and other related genes, reference genes and the like. According to the invention, angiogenesis-related signal molecules are concentrated on a flat plate; a real-time fluorescent quantitative PCR reaction is carried out to reflect the survival state of cells, human liver cancer Huh7 is compared with normal liver cells, possible ways of an angiogenesis signalpath in the human liver cancer and the normal liver cells are discussed, and most direct evidences are provided for research on regulation and control of key proteins; according to the invention, molecules related to the angiogenesis signal pathway are rapidly and accurately found from the transcriptional level, and a powerful tool is provided for mechanism discussion of new targeted drugs, development of angiogenesis related inhibitors and the like.

The invention relates to the field of biochemical detection, in particular to a primer set, a kit, a library and an application for the multi-gene combined detection of gynecological tumors. The primer set for the multi-gene combined detection of gynecological tumors can be used for carrying out specific amplification of 14 oncogenes APC, AKT1, BRAF, CTNNB1, EGFR, FBXW7, KRAS, NRAS, PIK3CA, PPP2R1A, PTEN, TP53, BRCA1 and BRCA2 in the same PCR reaction system. The invention also provides a kit comprising the above primer set, and the kit is based on multiplex PCR targeted capture technology, and can easily complete the enrichment of target sequences within 8 h and obtain the high-quality library which can be directly sequenced on the machine. Using the sequencing library constructed by thekit and combining with the second-generation sequencing technology, the mutations of 1% or lower can be detected, and the false positive rate is extremely low.

High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser / Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser / Thr kinase AKT1 is presented.

The invention discloses a method for preparing a Kinase protein Akt1 conditional gene knockout non-human mammal model and application of the method. The invention further discloses a method for screening compounds for preventing or treating cardiomegaly and glucose metabolic disorders by the Kinase protein Akt1 conditional gene knockout non-human mammal model, and application of the model that Akt1 and upstream and downstream biological signal transduction pathways of the Akt1 serve as medicine intervention targets to treat cardiomegaly and glucose metabolic disorders.

Disclosed herein is a gene therapeutic agent and pharmaceutical composition for the prevention and treatment of lung cancer. For aerosol delivery, chemically synthesized polyester amine is used as a carrier in the gene therapeutic agent. The polyester amine / Akt1 siRNA complex is found to be effectively delivered to the lungs of K-ras null mice through a nose-only inhalation system and to significantly suppress lung cancer progression as denoted by gene delivery efficiency and inhibition of Akt-related signals and cell cycle. Thus, the aerosol delivery of polyester amine-mediated Akt1 siRNA is provided as an effective model for noninvasive gene therapy.

The invention provides a PCR detection reagent for detecting liver cancer core signal molecules and an application thereof. The PCR detection reagent comprises PCR reaction primers for detecting ADAM17 genes, AKT1 genes, ANGPT2 genes, BAX genes, BCL2 genes, BCL2L1 genes and other related genes, reference genes and the like. According to the invention, liver cancer core signal molecules are concentrated on a flat plate; by performing one-time real-time fluorescent quantitative PCR reaction, the survival state of cells is reflected, and compared with human liver cancer Huh7 and normal liver cells, possible ways of liver cancer core signal molecules in the human liver cancer and the normal liver cells are discussed, and most direct evidences are provided for researching regulation and controlof key proteins; according to the invention, the liver cancer core signal molecule is rapidly and accurately found from the transcriptional level, and a powerful tool is provided for mechanism discussion of new targeting drugs, development of targeting liver cancer inhibitors and the like.

The invention relates to a medicine for treating postpartum depression and a preparation method of a preparation thereof, and belongs to the technical field of medicines. A formulation of the medicinedisclosed by the invention is prepared from Chinese angelica, herba leonuri and a corrigent. The preparation prepared can be used for treating depression, especially postpartum depression. Natural drug extraction and purification methods are adopted to prepare the preparation with pharmacological effects such as regulating mood, soothing liver and regulating qi, supplementing blood and promotingblood circulation. Active ingredients in the designed formulation and the preparation such as quercetin, caffeic acid, ferulic acid, safrol, cuparen, isoeugenol, 7-Hydroxy-3-butylidenephthalide, 3-Butylidene phthalide, senkyunolide C, genkwanin, wogonin, soybean aglycone, stachydrine and kaempferol synergistically act on key targets PTGS2, GABRA1 / 2 / 3, MAOB, SLC6A4, MAOA, AR, NOS2 / 3, AKT1, CASP3 and ESR1 for emotion regulation to mental disorders, autism and anxiety disorder, thus playing a role of treating depression, especially postpartum depression.

The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof.

A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.

The invention provides a pyrazolopyrimidine piperazinone compound as well as a preparation method and application thereof, and belongs to the field of organic compound synthesis and medical application. The structural formula of the pyrazolopyrimidine piperazinone compound is shown in the specification. Tests prove that the pyrazolopyrimidine piperazinone compound provided by the invention has strong inhibitory activity on Akt1 kinase, has anti-proliferative activity on mantle cell lymphoma (MCL) and has good practical application value.

The invention belongs to the technical field of biology, and discloses an application of an Akt1 phosphorylated PMS2 protein as an ovarian cancer treatment target, and a method for identifying the Akt1 phosphorylated PMS2 protein as the ovarian cancer treatment target comprises the following steps: detecting the relationship between activated Akt1 and p-PMS2 through Western Blot; detecting the change of the migration ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the invasion ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the clone formation ability of the ovarian cancer cells transfected with the PS2-T156A by a plate cloning method; and the influence of apoptosis of the transfected PMS < 2 >-T156A ovarian cancer cells is detected through a flow cytometry and Western Blot. The invention confirms that threonine at the site 156 of the PMS2 is phosphorylated by Akt1 for the first time, and provides a new direction and target for research and treatment of ovarian cancer.

The invention discloses a construction proposal that adopts a genetic engineering method to obtain the target knockdown expression of mRNA in cells, recombinant adenoviruses obtained by the proposal and a detailed application of eukaryotic expression plasmid to treating cancers. In the invention, U6 promoters which respectively aim at human beings and mice are inserted at the downstream of the multiple clone site; antisense Akt1, PI3K, p85 subunits and COX-2 insertion sequence segments are connected with the downstream of the U6 promoters; the obtained recombinant adenoviruses and the eukaryotic expression plasmid can be reproduced or multiplied in tumor cells of glioma, gastric cancer, mammary cancer, lung cancer and the like; the cDNA segment of the inserted antisense Akt1, PI3K, p85 subunits and COX-2 can realize high-efficiency expression in tumor cells and restrain the expression of Akt1, PI3K, p85 subunits and COX-2 of tumor cells, thus further affecting the expression of downstream genes (such as Mmps, Nfkb, p53, bax, caspases and the like) and having strong bystander effect against tumor cells. The adenoviruses and the eukaryotic expression plasmid have unique practicality in preparing tumor treating medicines and radiotherapy hypersensitivity.

The invention relates to the field of biomedical technology, a primer for detecting inflammatory cytokines in rats with rheumatoid arthritis and a method thereof are disclosed, when the test animals and their tissues are ready, total RNA was extracted from CIA rat joints, the purity and concentration of total RNA were detected, and 5 pairs of specific primers were synthesized by reverse transcription of total RNA. Using CIA rat cDNA as template, 15 [mu]L system PCR was used to detect total RNA. In the gel imaging system, the ultraviolet ray was separated by a partition plate, and the rat RelA,TLR4, AKT1, IL6, NF-kB cDNA fragment gel, rapid agarose gel DNA recovery kit, and ligation of the recovered DNA fragment to T-Vector, screening and sequencing of transformed blue and white spots. A CIA rat model is established, detecting the expression of NF-kB subunit p65, toll-like receptor 4, AKT serine / threonine kinase 1, interleukin 6 and NF-kB subunit in the joints of rats with rheumatoid arthritis by molecular biological methods is of great significance for the early prevention and treatment of RA. The results showed that the expression of NF-kB subunit p65, toll-like receptor 4, AKT serine / threonine kinase 1, interleukin 6 and NF-kB subunit in the joints of rats with rheumatoid arthritis was significantly higher than the of normal joints.

The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase, also known as Protein Kinase B, an enzyme that is believed to play a key role in the inhibition of apoptosis and thus in the etiology of cancer and other conditions, including neurodegenerative diseases. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the compounds with a target binding site derived from the crystal structure of a ternary complex involving Akt1, a nonhydrolyzable ATP analogue, and a peptide substrate derived from a physiological AKT substrate such that the protein active site is defined including those residues within a defined distance from the nonhydrolyzable ATP analogue; (3) ranking the docked compounds by goodness of fit; (4) further selecting compounds from compounds high ranked by goodness of fit in docking by using one or more screening criteria; (5) optionally, visually analyzing structures of compounds selected in step (4) to remove any compounds with improbable docking geometry; and (6) experimentally testing the selected compounds from step (4) or step (5), if step (5) is performed, to determine their inhibitory activity against Akt1 in order to select compounds with Akt1 inhibitory activity. The invention also encompasses pharmaceutical compositions including compounds whose inhibitory activity against Akt1 is discovered by the screening method, as well as methods of use of the pharmaceutical compositions to treat cancer and other conditions.

The invention belongs to the biological technical field and relates to an application of a KIT signal related gene QPCR (quantitative polymerase chain reaction) chip to the mouse piebaldism detection. The application of the KIT signal related gene QPCR chip to the mouse piebaldism detection is characterized in that the chip uses genes including Akt1, Bcl2, Cbl, Ccnd3, Ccnd3-ps, Csf1, Crk, Ecm1, Fes, Fyn, Grb7, Hras1, Jak1, Kitl, Lyn, Map2k, Matk, Myb, Nr0b2, Ntrk1, Pdgfa, Pik3ca, Ppp1r13b, Prkcc, Raf1, Sh2b2, Shc1, Snai2, Soat1, Stat1 and Zhx2 as detection sites, Actb is used as the internal reference, and the QPCR chip is used for QPCR amplification in the mouse piebaldism detection. Compared with the gene chip, the KIT signal related gene QPCR chip provided by the invention has the following advantages that 1, the cost is low; 2, the related gene is designed by aiming at a certain signal path or a certain tissue, and a certain specificity is realized; and 3, the operation and the data analysis are relatively simple.